Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Gains from Investment Securities (2018 - 2025)

Organogenesis Holdings (ORGO) has 8 years of Gains from Investment Securities data on record, last reported at $12.0 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 639.02% year-over-year to $12.0 million; the TTM value through Dec 2025 reached $12.0 million, up 668.95%, while the annual FY2025 figure was $12.0 million, 13.26% up from the prior year.
  • Gains from Investment Securities reached $12.0 million in Q4 2025 per ORGO's latest filing, up from $11.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $12.0 million in Q4 2025 and bottomed at -$914000.0 in Q2 2021.
  • Average Gains from Investment Securities over 5 years is $2.3 million, with a median of $675000.0 recorded in 2021.
  • The widest YoY moves for Gains from Investment Securities: up 8418.07% in 2024, down 216.44% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $6.6 million in 2021, then plummeted by 78.5% to $1.4 million in 2022, then crashed by 73.84% to $371000.0 in 2023, then skyrocketed by 336.39% to $1.6 million in 2024, then skyrocketed by 639.02% to $12.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $12.0 million in Q4 2025, $11.9 million in Q3 2025, and $19000.0 in Q2 2025.